XOSPATA – Patient Worthy

rawpixel / Pixabay

NMPA Grants Conditional Approval to XOSPATA for FLT3mut+ AML

Post author:Jessica Lynn
Post published:February 10, 2021
Post category:Acute Myeloid Leukemia Neutropenia Thrombocytopenia

In an early February press release, pharmaceutical company Astellas Pharma Inc. ("Astellas") shared that XOSPATA (gilteritinib) was given conditional approval in China for the treatment of patients with FLT3-mutated…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

NMPA Grants Conditional Approval to XOSPATA for FLT3mut+ AML

Why Your Voice in Research Matters: Groundbreaking Studies are Changing What's Possible

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Let’s Work Together!

Keep Up to Date

Learn More